Meeting
2021 ASCO Annual Meeting
Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.
Authors
Davendra Sohal
University of Cincinnati, Cincinnati, OH
Davendra Sohal , Mai T. Duong , Robert Boutin , Leon Lenchik , Jiyoon Kim , Namita Gandhi , Muhammad Shaalan Beg , Andrea Wang-Gillam , James Lloyd Wade III, Katherine A Guthrie , Elena Gabriela Chiorean , Syed A. Ahmad , Andrew M. Lowy , Howard S. Hochster , Philip Agop Philip , Victor Tsu-Shih Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT02562716
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4131)
DOI
10.1200/JCO.2021.39.15_suppl.4131
Abstract #
4131
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Non-responders to neoadjuvant chemotherapy in pancreatic adenocarcinoma: Characteristics and outcomes.
First Author: Brendan Hagerty
Poster
2019 ASCO Annual Meeting
Impact of body composition on outcomes from anti-programmed death-1 (PD-1) treatment.
First Author: Arissa Young
Poster
2019 Gastrointestinal Cancers Symposium
Baseline and longitudinal quantification of lean muscle mass using routine CT measurements prior to resection for pancreatic adenocarcinoma.
First Author: Paul Eliezer Oberstein
Poster
2022 ASCO Annual Meeting
Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).
First Author: Philip Agop Philip